VX-135 Pathway
Geoffrey Porges – Sanford Bernstein LLC: Congrats on the additional CF Phase 3 data. Perhaps just to drilling a little bit more on 135. Bob, could you let us know first what the primary metabolic pathway is for VX-135? Secondly, the thinking behind taking it up to the 400 milligram dose, and then what the outcome was for those patients with the elevated liver functions and lastly can you just tell us whether you’ve seen any transaminase elevation not enough to get to an say a discontinuation, but any et al at the 200 milligram dose?
Robert Kauffman – SVP and Chief Medical Officer: So I’ll take – if I could remember all four of those questions I’ll take them in order. The pathway of metabolism is just primarily routinely exceeded as most nukes are. In terms of why we went to 400 milligram dose? I would say that part of the Phase 2 evaluation of any compound really is to explore the dose range. When we had completed the 100 milligram and 200 milligram doses in the European study, we had very good tolerability and therefore we decided to dose escalate. We wanted to sort of maximize of viral kinetics in order to get the best response possible.
Geoffrey Porges – Sanford Bernstein LLC: The outcome of the elevated transaminase patients in that any at 200?
Robert Kauffman – SVP and Chief Medical Officer: Yeah, they were none at 200 nor at 100 and they all resolved really quite quickly within a week or so. In terms of the other transaminase elevations, I guess I just answer that by saying we really haven’t seen anything in the 100 milligram and 200 milligram groups.
Market Data 
Markets 
AI
